"The post hoc analysis from the pooled SUSTAIN and ASSURE clinical trials produced a 77% RRR of MACE in patients with DM for the entire group of patients. So there was no analysis conducted that separated the two statins vs placebo."

See Fig 6 and Fig 7 in this patent "COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION." They break down the cumulative 5-point MACE by statin type from the ASSURE trial. Apabetalone decreased MACE in both rosuvastatin and atorvastatin patients (Fig 6). Apabetalone worked extremely well in the presence of rosuvastatin to reduce MACE in those with below median HDL (Fig 7), though they don't show the atorvastatin subgroup here. Kind of low patient numbers because it is only ASSURE and not combined with SUSTAIN or ASSERT. Also, this is for all patients, not just diabetics. Keep in mind very few of the MACE events in the ASSERT/SUSTAIN/ASSURE post-hoc were cardio death, non-fatal MI or non-fatal stroke (3-point MACE). But it still gives some information to chew on.

BDAZ